Denali Therapeutics Reports the Initiation of P-I/II Clinical Trial of DNL593 (PTV:PGRN) for the Treatment of Frontotemporal Dementia-Granulin
Shots:
- The company initiates patients dosing in the three-part P-I/II trial to evaluate the safety, PK & PD of DNL593 in patients with FTD caused by mutations in GRN. The company is expected to initiate the patients dosing in H2’22
- In preclinical studies, therapy showed an increase of PGRN levels in the brain including neurons & microglia, improved lysosomal function
- Denali & Takeda collaborated to co-develop & co-commercialize DNL593. Denali receives milestones upon achievement of clinical, regulatory & sales-based milestones & will share the development & commercialization costs equally. DNL593 is a brain-penetrant, recombinant PGRN replacement therapy that has been developed by PTV technology
Ref: Globe Newswire | Image: Denali
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
